ALNYLAM PHARMACEUTICALS INC (ALNY)
US02043Q1076 - Common Stock
Overall ALNY gets a fundamental rating of 4 out of 10. We evaluated ALNY against 564 industry peers in the Biotechnology industry. While ALNY seems to be doing ok healthwise, there are quite some concerns on its profitability. ALNY is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
ALNY had negative earnings in the past year.
In the past year ALNY had a positive cash flow from operations.
In the past 5 years ALNY always reported negative net income.
ALNY had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of ALNY (-7.90%) is better than 88.41% of its industry peers.
ALNY has a worse Return On Equity (-1026.96%) than 83.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.9% | ||
| ROE | -1026.96% | ||
| ROIC | N/A |
ROA(3y)-22.27%
ROA(5y)-25.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALNY has a Gross Margin of 85.37%. This is amongst the best in the industry. ALNY outperforms 88.77% of its industry peers.
In the last couple of years the Gross Margin of ALNY has declined.
ALNY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y-3.18%
2. Health
2.1 Basic Checks
ALNY does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALNY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALNY has been increased compared to 5 years ago.
ALNY has a better debt/assets ratio than last year.
2.2 Solvency
ALNY has an Altman-Z score of 2.94. This is not the best score and indicates that ALNY is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.94, ALNY is doing good in the industry, outperforming 75.40% of the companies in the same industry.
The Debt to FCF ratio of ALNY is 63.93, which is on the high side as it means it would take ALNY, 63.93 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of ALNY (63.93) is better than 91.98% of its industry peers.
A Debt/Equity ratio of 31.64 is on the high side and indicates that ALNY has dependencies on debt financing.
With a Debt to Equity ratio value of 31.64, ALNY is not doing good in the industry: 84.85% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 31.64 | ||
| Debt/FCF | 63.93 | ||
| Altman-Z | 2.94 |
ROIC/WACCN/A
WACC10.5%
2.3 Liquidity
A Current Ratio of 2.75 indicates that ALNY has no problem at all paying its short term obligations.
The Current ratio of ALNY (2.75) is worse than 68.09% of its industry peers.
A Quick Ratio of 2.69 indicates that ALNY has no problem at all paying its short term obligations.
The Quick ratio of ALNY (2.69) is worse than 67.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.75 | ||
| Quick Ratio | 2.69 |
3. Growth
3.1 Past
ALNY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.71%, which is quite impressive.
ALNY shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.54%.
Measured over the past years, ALNY shows a very strong growth in Revenue. The Revenue has been growing by 89.46% on average per year.
EPS 1Y (TTM)36.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-175.65%
Revenue 1Y (TTM)21.54%
Revenue growth 3Y54.8%
Revenue growth 5Y89.46%
Sales Q2Q%-33.26%
3.2 Future
The Earnings Per Share is expected to grow by 42.65% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALNY will show a very strong growth in Revenue. The Revenue will grow by 24.81% on average per year.
EPS Next Y42.55%
EPS Next 2Y28.39%
EPS Next 3Y39.67%
EPS Next 5Y42.65%
Revenue Next Year22.69%
Revenue Next 2Y19.68%
Revenue Next 3Y24.41%
Revenue Next 5Y24.81%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ALNY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALNY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALNY indicates a rather cheap valuation: ALNY is cheaper than 91.98% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1901.11 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ALNY's earnings are expected to grow with 39.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.39%
EPS Next 3Y39.67%
5. Dividend
5.1 Amount
ALNY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALNYLAM PHARMACEUTICALS INC
NASDAQ:ALNY (12/30/2024, 8:00:00 PM)
Premarket: 239.49 +3.48 (+1.47%)236.01
-1.96 (-0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.89%
Inst Owner Change3.91%
Ins Owners0.38%
Ins Owner Change1.41%
Market Cap30.44B
Analysts78.95
Price Target309.18 (31%)
Short Float %2.65%
Short Ratio4.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.1%
Min EPS beat(2)4%
Max EPS beat(2)88.19%
EPS beat(4)4
Avg EPS beat(4)41.89%
Min EPS beat(4)4%
Max EPS beat(4)88.19%
EPS beat(8)7
Avg EPS beat(8)41%
EPS beat(12)7
Avg EPS beat(12)16.23%
EPS beat(16)9
Avg EPS beat(16)11.09%
Revenue beat(2)1
Avg Revenue beat(2)18.89%
Min Revenue beat(2)-7.88%
Max Revenue beat(2)45.66%
Revenue beat(4)2
Avg Revenue beat(4)12.13%
Min Revenue beat(4)-7.88%
Max Revenue beat(4)45.66%
Revenue beat(8)5
Avg Revenue beat(8)16.83%
Revenue beat(12)6
Avg Revenue beat(12)8.67%
Revenue beat(16)9
Avg Revenue beat(16)7.05%
PT rev (1m)0.08%
PT rev (3m)4.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)36.04%
EPS NY rev (1m)1.8%
EPS NY rev (3m)21.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)19.22%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14.53 | ||
| P/FCF | 1901.11 | ||
| P/OCF | 538.71 | ||
| P/B | 940.86 | ||
| P/tB | 940.86 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.62
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)0.12
FCFY0.05%
OCF(TTM)0.44
OCFY0.19%
SpS16.24
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.9% | ||
| ROE | -1026.96% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.37% | ||
| FCFM | 0.76% |
ROA(3y)-22.27%
ROA(5y)-25.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y-3.18%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 31.64 | ||
| Debt/FCF | 63.93 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 72.37% | ||
| Cap/Sales | 1.93% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.75 | ||
| Quick Ratio | 2.69 | ||
| Altman-Z | 2.94 |
F-Score6
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)145.87%
Cap/Depr(5y)291.01%
Cap/Sales(3y)6.47%
Cap/Sales(5y)19.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-175.65%
EPS Next Y42.55%
EPS Next 2Y28.39%
EPS Next 3Y39.67%
EPS Next 5Y42.65%
Revenue 1Y (TTM)21.54%
Revenue growth 3Y54.8%
Revenue growth 5Y89.46%
Sales Q2Q%-33.26%
Revenue Next Year22.69%
Revenue Next 2Y19.68%
Revenue Next 3Y24.41%
Revenue Next 5Y24.81%
EBIT growth 1Y46.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year74.63%
EBIT Next 3Y67.51%
EBIT Next 5Y76.54%
FCF growth 1Y102.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y110.1%
OCF growth 3YN/A
OCF growth 5YN/A